Laboratory of Pharmaceutical Technology, CIRM, Department of Pharmacy, University of Liege, B36, Tour 4, Avenue de l'hôpital, 1, 4000, Liege, Belgium.
AAPS PharmSciTech. 2010 Jun;11(2):966-75. doi: 10.1208/s12249-010-9463-3. Epub 2010 May 29.
To investigate the encapsulation of Print 3G, a peptidic agent that could reduce the angiogenic development of breast tumors, pegylated liposomes used as intravenous vectors were studied and characterized. Recently, the path of liposomes has been explored with success to improve the pharmacological properties of peptidic drugs and to stabilize them. In this study, loaded unilamellar vesicles composed of SPC:CHOL:mPEG2000-DSPE (47:47:6) were prepared by the hydration of lipid film technique. An HPLC method was developed and validated for the determination of Print 3G to calculate its encapsulation efficiency. Observed Print 3G adsorption on different materials employed during liposome preparation (such as glass beads, tubing, and connections for extrusion) led to the modification of the manufacturing method. The freeze-thawing technique was used to enhance the amount of Print 3G encapsulated into blank liposomes prepared using the hydration of lipid film procedure. Many factors may influence peptide entrapment, namely the number of freeze-thawing cycles, the lipid concentration, the peptide concentration, and the mixing time. Consequently, a design of experiments was performed to obtain the best encapsulation efficiency while minimizing the number of experiments. The lipid concentration and the number of freeze-thawing cycles were identified as the positive factors influencing the encapsulation. As a result of the optimization, an optimum was found and encapsulation efficiencies were improved from around 30% to 63%. Liposome integrity was evaluated by photon correlation spectroscopy and freeze-fracture electron microscopy to ensure that the selected formulation possesses the required properties to be a potential candidate for further in vitro and in vivo experiments.
为了研究可减少乳腺癌血管生成发展的肽类药物 Print 3G 的包封,研究并表征了用作静脉载体的聚乙二醇化脂质体。最近,已经成功探索了脂质体途径,以改善肽类药物的药理学性质并稳定它们。在这项研究中,通过脂质体薄膜水化技术制备了由 SPC:CHOL:mPEG2000-DSPE(47:47:6)组成的单层载药囊泡。开发并验证了一种 HPLC 方法来测定 Print 3G 的含量,以计算其包封效率。观察到 Print 3G 在脂质体制备过程中使用的不同材料(如玻璃珠、管和挤出连接)上的吸附,导致了制造方法的修改。冻融技术用于增强通过脂质体薄膜水化程序制备的空白脂质体中封装的 Print 3G 的量。许多因素可能会影响肽的包封,例如冻融循环的次数、脂质浓度、肽浓度和混合时间。因此,进行了实验设计以在最小化实验次数的同时获得最佳的包封效率。确定了脂质浓度和冻融循环次数是影响包封的正因素。通过优化,找到了最佳条件,包封效率从约 30%提高到 63%。通过光子相关光谱法和冷冻断裂电子显微镜评估了脂质体的完整性,以确保所选配方具有进行进一步的体外和体内实验的所需特性。